anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Spending more time outdoors was treated as a safe and cost-effective method to prevent and control myopia. While prior research has established an inverse association between outdoor time and the risk of myopia onset, the effect of increasing outdoor time in delaying the progression of myopia remains a subject of debate. The present meta-analysis aimed to assess the relationship between outdoor time and the myopia onset, and further examine whether there is a dose-response relationship between outdoor time and the risk of myopia onset. Meanwhile, perform whether the outdoor time is related to delaying the progression of myopia.
METHODS: Studies were retrieved from PubMed, Web of Science, Embase, Medline, and the Cochrane Database, spanning from their inception to February 2023. Three cohort studies and 5 prospective intervention studies were included, with a total of 12,922 participants aged 6-16 years.
RESULTS: Comparing the highest with the lowest exposure levels of time spent outdoors, the highest outdoor time was strongly associated with a reduced risk of myopia onset (odds ratio [OR]: 0.53; 95% confidence interval [CI]: 0.34, 0.82). A nonlinear dose-response relationship was found between outdoor time and myopia onset risk. Compared to 3.5 h of outdoor time per week, an increase to 7, 16.3, and 27 h per week corresponded with a respective reduction in the risk of myopia onset by 20%, 53%, and 69%. Among children and adolescents who were not myopic, spending more time outdoors significantly slowed down the speed of change in spherical equivalent refractive (weighted mean difference [WMD] = 0.10D, 95% CI: 0.07, 0.14) and axial length (WMD = -0.05 mm, 95% CI: -0.06, -0.03). Among children and adolescents who were already myopic, spending more time outdoors did not slow myopia progression.
CONCLUSIONS: Overall, spending more time outdoors can prevent the onset of myopia, but it does not seem to slow its progression. Further studies are needed to better understand these trends.
Each participant in the control arm will attend a total of 10 treatment visits (one visit per week), over the course of 10 weeks. Participants in the control arm will receive electrical stimulation at non-disease related acu-points for approximately 1 hour per session.
PURPOSE:To obtain the title powder causing no agglomeration, outstanding in adsorption effect and dispersion stability, and dermal ointments, deodorants and oral composition using said powder excellent in the above characteristics, by coating the surface of powdery nuclei with magnesium metasilicatealuminate. CONSTITUTION:The objective powder can be obtained by coating the surface of powdery nuclei with magnesium metasilicatealuminate or its combination with at least one kind of other powder. Said powdery nuclei is e.g. of organic material such as polyolefin resin, rubber, chitin, keratin or cellulose, or of inorganic material such as talc, mica, titanium dioxide or barium sulfate. For said other powder to be used in combination with the magnesium metasilicatealuminate, the above organic or inorganic powder can be used. It is preferable that 0.1-200pts.wt. of the magnesium metasilicatealuminate the used based on 100pts.wt. of the powdery nuclei (plus other powder).
Chagas disease (CD), caused by the flagellated protozoan Trypanosoma cruzi (T. cruzi), affects approximately 7 million people worldwide and is endemic in Latin America, especially among socioeconomically disadvantaged populations. Since the 1960s, only two drugs have been commercially available for treating this illness: nifurtimox (NFX) and benznidazole (BZN). Although these drugs are effective in the acute phase (AP) of the disease, in which parasitemia is usually high, their cure rates in the chronic phase (CP) are low and often associated with several side effects. The CP is characterized by a subpatent parasitaemia and absence of clinical symptoms in the great majority of infected individuals. However, at least 30 % of the individuals will develop potentially lethal symptomatic forms, including cardiac and digestive manifestations. For such reason, in the CP the treatment is usually symptomatic and typically focuses on managing complications such as arrhythmias, heart failure, or digestive problems. Therefore, the need for new drugs or therapeutic approaches using BZN or NFX is extremely urgent. This review presents the main clinical trials, especially in the CP, which involve BZN and NFX in different treatment regimens. Additionally, other therapies using combinations of these drugs with other substances such as allopurinol, itraconazole, ravuconazole, ketoconazole, posaconazole and amiodarone are also reported. The importance of early diagnosis, especially in pediatric patients, is also discussed, emphasizing the need to identify the disease in its early stages to improve the chances of successful treatment.
70 subjects will be randomly allocated into 2 groups, using a computer generated table of random numbers. Group A (study group) will receive lidocaine. Group B (control group) will receive the same volume of saline infusion. The study drugs will be prepared by one of the investigators in the study. Subjects will be recruited up to 21 days prior to surgery.They will be premedicated with intravenous (IV) midazolam 0.04 mg/kg. Routine ASA monitors will be applied. Anesthesia will be induced with remifentanil infusion started at 0.1 mcg/kg/minute titrated to keep blood pressure within 20% of the baseline and propofol 1.0 -2.0 mg/kg. Group A will receive lidocaine 1.5mg/kg bolus and Group B the equivalent volume of saline. Subjects will be monitored with a 5 lead EKG throughout the lidocaine administration and if any arrhythmia is detected. The study drug will be stopped and investigators unblinded.

Tracheal intubation will be facilitated with rocuronium (0.6 mg/kg) or succinylcholine (1-2mg /kg). Immediately after the induction, group A will receive lidocaine infusion (2 mg/kg/hr IV). Group B will receive the equivalent volume of saline; both infusions will be continued until 1 hour after arrival in the PACU. Anesthesia will be maintained with desflurane titrated to maintain a bispectral index (BIS) between 40-60 , remifentanil infusion started at 0.1mcg/kg/min titrated to keep blood pressure within 20 % of baseline values , and rocuronium that will be administered at the discretion of the anesthesiologist. Upon termination of the surgery, neuromuscular blockade will be antagonized with a combination of neostigmine 0.05mg/kg and glycopyrrolate 0.01 mg/kg. Ondansetron 4 mg IV will be administered to prevent postoperative nausea and vomiting. Subject will be evaluated for pain in the OR after extubation, using a numeric rating scale, if pain greater than 4/10 they will receive hydromorphone (10 mcg/kg IV). In PACU, subjects will receive IV hydromorphone in divided doses as needed to achieve a verbal rating score for pain \<4 out of 10 and they will be evaluated every 15 minutes .They will also receive metoclopramide (20 mg IV ) as rescue antiemetic in PACU. Discharge readiness will be assessed by a PACU nurse using the modified Post Anesthesia Discharge Scoring System (MPADSS) score every 15 minutes for about 3 hours or until ready for discharge.The primary and secondary outcomes will be assessed by an independent observer who will be blinded to group allocation. Study personnel will contact the subject at 24 hours to assess well being, (nausea, vomiting and opioid consumption. Subject will be contacted by telephone by the study staff and will complete the Modified Quality of Recovery 40 (MQOR40) at 24 hours post surgery.
DT 2658785 described a premix contg. filings and mixed with mercury to obtain a dental filler which hardens at the temp. of the human body. The premix also contained skeleton- or reinforcing bodies (2) made of an Ag-Sn-Cu alloy and coated with a layer (3) of copper formed by chemical- or electroplating. The novelty in the present invention is that the Cu coating (3) is covered by a protective layer (4) of metal, which pref. forms an amalgam and has superior oxidn.- and corrosion-resistance to Cu (3) when the premix is stored prior to use. Metal (4) is pref. a noble metal, esp. silver, which is also present in the premix, and layer (4) is pref. 1 mu thick so it allows the Cu to participate in reactions when Hg is added to make the dental filler. With the original invention, the Cu coating (3) on skeletons (2) oxidised and interfered with the desired amalgamation. The Ag (4) prevents oxidn. of the Cu (3).
PURPOSE:To obtain an inhalant for the treatment and prevention of cardiac insufficiency, containing a specific dihydropyridine derivative or its salt as an active component and effective for lowering the left ventricular end diastolic pressure and pulmonary capillary pressure without largely depressing the systemic blood pressure or lowering the cardiac function. CONSTITUTION:This inhalant for the treatment and prevention of cardiac insufficiency contains a dihydropyridine derivative expressed by formula (R<1> to R<3> each is a lower alkyl; A is a 2-6C unsaturated chain hydrocarbon residue) or its salt as an active component. The compound of formula is especially preferably methyl 3-phenyl-2-propenyl-l,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl) pyridine-3-5-dicarboxylate. The cardiac insufficiency is e.g. myocardial infarction, infectious endocarditis, pericardial tamponade, myocarditis, cardiac myopathy, heart valve disease, congenital heart disease, right ventricular myocardial infarction, brain embolism, pulmonary infarction, acute tricuspid incompetence, chronic left ventricular failure and chronic right ventricular failure. The daily dose of the compound of formula is preferably about 0.001-0.1mg per 1kg body weight.
Type 1 diabetes (T1D) is a chronic condition in which beta cells are destroyed by immune cells. Despite progress in immunotherapies that could delay T1D onset, early detection of autoimmunity remains challenging. Here, we evaluate the utility of machine learning for early prediction of T1D using single-cell analysis of islets. Using gradient-boosting algorithms, we model changes in gene expression of single cells from pancreatic tissues in T1D and non-diabetic organ donors. We assess if mathematical modeling could predict the likelihood of T1D development in non-diabetic autoantibody-positive donors. While most autoantibody-positive donors are predicted to be non-diabetic, select donors with unique gene signatures are classified as T1D. Our strategy also reveals a shared gene signature in distinct T1D-associated models across cell types, suggesting a common effect of the disease on transcriptional outputs of these cells. Our study establishes a precedent for using machine learning in early detection of T1D.
INTRODUCTION: Practical simulation training with proper haptic feedback and the fragility of the human body is required to overcome the long learning curve associated with laparoscopic inguinal hernia repair (LIHR). However, few hernia models accurately reflect the texture and fragility of the human body. Therefore, in this study, we developed a novel model for transabdominal preperitoneal (TAPP) LIHR training and evaluated its validity.
METHODS: We developed a high-quality mock peritoneum with a hydrated polyvinyl alcohol layer and a unique two-way crossing cellulose fiber layer. To complete the simulation, the peritoneum was adhered to a urethane foam inguinal base with surgical landmarks. Participants could perform all the procedures required for the TAPP LIHR. Twenty-four surgeons performed TAPP LIHR simulation using a novel simulator. Their opinions were rated on a 5-point Likert scale. Additionally, 6 surgical residents and 10 surgical experts performed the procedure. Their performance was evaluated using the TAPP checklist score and procedure time.
RESULTS: Most participants strongly agreed that the TAPP LIHR simulator with an exchangeable peritoneum model was useful. The participants agreed on the model fidelity for tactile sensation, forceps handling, and humanlike anatomy. In comparisons between surgical residents and experts, the experts had significantly higher scores (10.6 vs. 17.2, p < 0.05) and shorter procedure times (92.3 vs. 55.9 min; p < .05) than did surgical residents.
CONCLUSIONS: We developed a high-quality exchangeable peritoneal model that mimics the human peritoneum's texture and fragility. This model enhances laparoscopic simulation training, potentially shortening TAPP LIHR learning curves.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly to cardiology, and concerns normalising the functional responsiveness of cardiovascular system in elderly and senile patients suffering arterial hypertension and metabolic syndrom. That is ensured by estimating the condition of functional reactivity of the CVS in psychoemotional load by recording systolic, diastolic, average dynamic pressure (BPav.dyn.) and heart rate (HR). These data are used to evaluate a functional responsiveness index (FRI) before and after load by formula: FRI=(BPav.dyn. x HR)100 (standard units). The value PFR increased more than by 20 standard units requires the complex therapy including individually prescribed hypocaloric diet calculated by formula considering sex and age and body weight, graduated static and dynamic physical activity, and introduction of irbesartan in dosage 150 mg once in the morning, and pioglitazone in dosage 30 mg once in the morning at least for 3 months. ^ EFFECT: complex drug-induced and drug-free therapy combined with empirically prescribed treatment length provides normalisation of functional responsiveness of the CVS in the given group of patients due to potentiation of therapeutic effect of separate components of an individual care. ^ 2 ex
Rasagiline 1 milligram (mg), orally, once daily for up to 24 months. Participants received interventions as part of routine medical care.
Stem cells from the apical papilla(SCAPs) exhibit remarkable tissue repair capabilities, demonstrate anti-inflammatory and pro-angiogenic effects, positioning them as promising assets in the realm of regenerative medicine. Recently, the focus has shifted towards exosomes derived from stem cells, perceived as safer alternatives while retaining comparable physiological functions. This study delves into the therapeutic implications of exosomes derived from SCAPs in the methionine-choline-deficient (MCD) diet-induced mice non-alcoholic steatohepatitis (NASH) model. We extracted exosomes from SCAPs. During the last two weeks of the MCD diet, mice were intravenously administered SCAPs-derived exosomes at two distinct concentrations (50 μg/mouse and 100 μg/mouse) biweekly. Thorough examinations of physiological and biochemical indicators were performed to meticulously evaluate the impact of exosomes derived from SCAPs on the advancement of NASH in mice induced by MCD diet. This findings revealed significant reductions in body weight loss and liver damage induced by the MCD diet following exosomes treatment. Moreover, hepatic fat accumulation was notably alleviated. Mechanistically, the treatment with exosomes led to an upregulation of phosphorylated adenosine monophosphate-activated protein kinase (p-AMPK) levels in the liver, enhancing hepatic fatty acid oxidation and transporter gene expression while inhibiting genes associated with fatty acid synthesis. Additionally, exosomes treatment increased the transcription levels of key liver mitochondrial marker proteins and the essential mitochondrial biogenesis factor. Furthermore, the levels of serum inflammatory factors and hepatic tissue inflammatory factor mRNA expression were significantly reduced, likely due to the anti-inflammatory phenotype induced by exosomes in macrophages. The above conclusion suggests that SCAPs-exosomes can improve NASH.
<P>PROBLEM TO BE SOLVED: To acquire information related to the dosing state of a subject or transition of the number of subjects in a clinical trial at real time.  <P>SOLUTION: The clinical trial monitoring system comprises a portable terminal, a server communicable with the portable terminal, and a client terminal communicable with the server. The portable terminal includes an input means for a subject to input clinical trial execution information, and a clinical trial execution information transmitting means for transmitting the clinical trial execution information to the server. The server includes a clinical trial execution information receiving means for receiving the clinical trial execution information from the portable terminal, a processing means for performing statistic processing to the clinical trial execution information to create monitoring information, and a monitoring information transmitting means for transmitting the monitoring information to the client terminal. The client terminal includes a display screen, a monitoring information receiving means for receiving the monitoring information from the server, and a display control means for displaying the monitoring information on a display screen.  <P>COPYRIGHT: (C)2008,JPO&INPIT
It includes at least one keratolytic and cerumenilytic cleaning agent, one bactericide agent, one yeast control agent and one anti-irritant and anti- pruriginous agent. Furthermore, it may include at least one agent that enhances its cerumenilytic properties, at least one vegetable extract with antiseptic and cicatrizant properties and/or at least one deodorant agent.   The agent with cleaning keratolytic action and cerumenilytic is lactic acid, salicylic acid, or a mixture of the two. The bactericide agent is Cetraria islandica extract. The yeast control agent is lactic acid, salicylic acid or a mixture of the two. The anti- irritant and anti-pruriginous is a vegetal extract of  Cucumis sativus. The agent that enhances the cerumenilytic effect is oleic acid. The vegetal extract is Mimosa tenuiflora extract, Cetraria islandica extract, Camomilla recutica extract or a mixture of them. The deodorant is Cetraria islandica extract.
The present invention discloses a traditional Chinese medicine composition for treating red external injuries, which is composed of raw materials of the following percent by weight: 1 to 3 wt% of each of angelica, sanchi, diverse wormwood herb, angelicae pubescentis, crab bone, dragon bone and tall gastrodis tuber, 5 to 7 wt% of each of eucommia bark, ledebouriella root, dahurian angelica, arisaema tuber, dragon blood and safflower, 4 to 6 wt% of each of eupolyphaga, chuanxiong rhizome and curare and 14 to 18 wt% of myrrh and frankincense. The present invention also provides a preparation method for the traditional Chinese medicine composition for treating external injuries. Compared with congeneric medicines, the traditional Chinese medicine composition has the characteristics of fast hemostasia and good hemostasia effect, and can promote wound healing. The traditional Chinese medicine composition has an especially obvious effect on overmuch hemorrhage caused by injuries from fall or other reasons. The traditional Chinese medicine composition has a good cure effect on the disunion of canker caused by all external injuries, and has a favorable tissue regeneration promotion function. The traditional Chinese medicine composition has a favorable pain alleviation curative effect and a favorable detumescence curative effect on flare or blood stasis caused by wrick and falling injuries when the traditional Chinese medicine composition is applied to or is coated on flare regions or blood stasis regions.
<P>PROBLEM TO BE SOLVED: To provide a medical image filing system permitting easy preparation of a record of using of treatment instruments used in an examination.  <P>SOLUTION: The treatment instruments which may be used for the examination are registered in the filing system before the examination. The names of the treatment instruments used in the examination are saved as information by using an RFID (radiofrequency interference device), or the like, in the examination. When a record of implementation of the examination is prepared after the examination, the saved names of the treatment instruments, or the like, are listed up on a display screen. When the record of implementation is modified or added, a list of names of treatment instruments which are actually used or may possibly be used in the examination are displayed on the display screen based on the kind, or the like, of an endoscope used in the examination. As a doctor or nurse selects the treatment instrument used in the examination among the list, the record of implementation can be easily prepared.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Participants randomized to receive relebactam 125 mg will be administered 125 mg doses of relebactam IV, in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
BACKGROUND: Critical COVID-19 survivors are at risk of developing Post-intensive Care Syndrome (PICS) and Chronic ICU-Related Pain (CIRP). We determined whether a specific care program improves the quality of life (QoL) of patients at risk of developing PICS and CIRP after COVID-19.
METHODS: The PAIN-COVID trial was a parallel-group, single-centre, single-blinded, randomized controlled trial. The intervention consisted of a follow up program, patient education on PICS and pain, and a psychological intervention based on Rehm's self-control model in patients with abnormal depression scores (≥8) in the Hospital Anxiety and Depression Scale (HADS) at the baseline visit. QoL was evaluated with the 5-level EQ 5D (EQ 5D 5 L), mood disorders with the HADS, post-traumatic stress disorder (PTSD) with the PCL-5 checklist, and pain with the Brief Pain Inventory short form, the Douleur Neuropathique 4 questionnaire, and the Pain Catastrophizing Scale. The primary outcome was to determine if the program was superior to standard-of-care on the EQ visual analogue scale (VAS) at 6 months after the baseline visit. The secondary outcomes were EQ VAS at 3 months, and EQ index, CIRP incidence and characteristics, and anxiety, depression, and PTSD at 3 and 6 months after baseline visits.
CONCLUSIONS: This program was not superior to standard care in improving QoL in critical COVID-19 survivors as measured by the EQ VAS. However, our data can help establish better strategies for the study and management of PICS and CIRP in this population.
TRIAL REGISTRATION: # NCT04394169, registered on 5/19/2020.
This cohort will include multimodal imaging sequences (3D T1-weighted imaging, 3D FLAIR, diffusion kurtosis imaging \[DKI\], arterial spin labeling \[ASL\], vascular water exchange imaging \[VEXI\], and resting-state functional MRI \[rest-fMRI\]). Detailed demographic information, neuropsychological assessments, standardized questionnaires, and basic physical examinations will also be collected. Multimodal neuroimaging data and neuropsychological assessments will be followed up twice (at 1 year and 2 years).
Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate.

Tamsulosin hydrochloride is (-)-(R)-5-[2-[[2-(o-Ethoxyphenoxy) ethyl]amino]propyl]-2-methoxybenzenesulfonamide, monohydrochloride. Tamsulosin hydrochloride USP is a white or almost white crystalline powder that melts with decomposition at approximately 230°C. It is sparingly soluble in water and methanol, slightly soluble in glacial acetic acid and ethanol, and practically insoluble in ether.

The molecular formula of tamsulosin hydrochloride is C20H28N2O5S • HCl. The molecular weight of tamsulosin hydrochloride is 444.98.

Each tamsulosin hydrochloride capsule, USP for oral administration contains tamsulosin hydrochloride USP 0.4 mg, and the following inactive ingredients: calcium stearate, FD&C Blue 2, gelatin, iron oxide red, iron oxide yellow, microcrystalline cellulose, methacrylic acid copolymer dispersion, sodium lauryl sulfate, talc, triacetin, and titanium dioxide. The capsules are printed with SW-9008 Black Ink containing black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, shellac, and strong ammonia solution.